Clinical Trial Update: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing coformulated favezelimab/pembrolizumab to physician's choice chemotherapy in PD-(L)1-refractory classical Hodgkin lymphoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Favezelimab (favezelimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED